Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly EBIT Margin of 97.11% in Q1 2026, down 37.69% quarter-over-quarter from 70.53% in Q4 2025, and down 1512.0% year-over-year from 6.88% in Q1 2025.
Vanda Pharmaceuticals' EBIT Margin history runs 17 years deep, the most recent figure standing at 97.11% for Q1 2026.
- In Q1 2026, EBIT Margin fell 1512.0% year-over-year to 97.11%; the TTM figure through Mar 2026 stood at 73.64% (down 3765.0% YoY), while the FY2025 annual figure was 69.95%, down 4950.0% from the prior year.
- EBIT Margin came in at 97.11% for Q1 2026 at Vanda Pharmaceuticals, down from 70.53% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 10.28% in Q4 2022 to a low of 97.11% in Q1 2026.
- A 5-year average of 28.57% and a median of 19.33% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin soared 1595 bps in 2023 and slumped 6253 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' EBIT Margin stood at 10.28% in 2022, then tumbled by 252 bps to 15.67% in 2023, then slipped by 23 bps to 19.33% in 2024, then plunged by 265 bps to 70.53% in 2025, then slumped by 38 bps to 97.11% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 97.11%, 70.53%, and 55.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -97.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.11% |
| Dec 31, 2025 | -70.53% |
| Sep 30, 2025 | -55.61% |
| Jun 30, 2025 | -73.21% |
| Mar 31, 2025 | -81.99% |
| Dec 31, 2024 | -19.33% |
| Sep 30, 2024 | -23.08% |
| Jun 30, 2024 | -20.10% |
| Mar 31, 2024 | -19.46% |
| Dec 31, 2023 | -15.67% |
| Sep 30, 2023 | -15.45% |
| Jun 30, 2023 | -6.23% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 10.28% |
| Sep 30, 2022 | 5.98% |
| Jun 30, 2022 | 5.38% |
| Mar 31, 2022 | -12.74% |
| Dec 31, 2021 | 12.70% |
| Sep 30, 2021 | 15.43% |
| Jun 30, 2021 | 18.22% |
| Mar 31, 2021 | 16.50% |
| Dec 31, 2020 | 15.45% |
| Sep 30, 2020 | 12.84% |
| Jun 30, 2020 | 14.74% |
| Mar 31, 2020 | -0.22% |
| Dec 31, 2019 | 6.96% |
| Sep 30, 2019 | 18.09% |
| Jun 30, 2019 | 16.75% |
| Mar 31, 2019 | -4.37% |
| Dec 31, 2018 | 17.25% |
| Sep 30, 2018 | 12.69% |
| Jun 30, 2018 | 8.26% |
| Mar 31, 2018 | 5.60% |
| Dec 31, 2017 | -4.86% |
| Sep 30, 2017 | -11.91% |
| Jun 30, 2017 | -4.57% |
| Mar 31, 2017 | -21.13% |
| Dec 31, 2016 | -1.71% |
| Sep 30, 2016 | -1.70% |
| Jun 30, 2016 | -13.29% |
| Mar 31, 2016 | -37.51% |
| Dec 31, 2015 | -46.76% |
| Sep 30, 2015 | -33.66% |
| Jun 30, 2015 | -19.79% |
| Mar 31, 2015 | -46.47% |
| Dec 31, 2014 | 453.44% |
| Sep 30, 2014 | -9.80% |
| Jun 30, 2014 | -198.91% |
| Mar 31, 2014 | -290.69% |
| Dec 31, 2013 | -88.71% |
| Sep 30, 2013 | -62.36% |
| Jun 30, 2013 | -41.03% |
| Mar 31, 2013 | -56.58% |
| Dec 31, 2012 | -81.16% |
| Sep 30, 2012 | -65.09% |
| Jun 30, 2012 | -96.50% |
| Mar 31, 2012 | -102.16% |
| Dec 31, 2011 | -70.59% |
| Sep 30, 2011 | -41.32% |
| Jun 30, 2011 | -20.36% |
| Mar 31, 2011 | 0.09% |
| Dec 31, 2010 | -16.48% |
| Sep 30, 2010 | 10.25% |
| Jun 30, 2010 | 75.03% |